In a study involving 250 military veterans, researchers have reported identifying and testing gene expression biomarkers whose levels rise with human stress.
Its most advanced gene expression signatures are for infectious disease diagnostics and are aimed at enabling the appropriate prescription of antiviral and antibiotic medications.
The company plans to commercialize a gene expression signature to predict recurrence risk in cutaneous squamous cell carcinoma.
Neurovascular Diagnostics intends to commercialize a test for unruptured intracranial aneurysm tests that use RNA expression signatures.
Test volume was up 5 percent, but the company's total revenue of $83.8 million was negatively affected by hurricanes in the US, company executives said.
The company believes it can overcome its challenges, and highlighted strong continued interest from pharma despite a disappointing end to its Merck deal.
The company saw total revenues of $27 million and product revenues of $16.9 million, as it had estimated in preliminary earnings report last month.
The firm's recent funding round will support its CLIA-certified laboratory that opened last year and the launch of its first RNA-based diagnostic test.
The firm will sell 855,000 shares of its common stock to three investors. It will also sell warrants to the same investors.
Agendia, which makes the MammaPrint test, called the report "disappointing" but thinks it still has a shot at landing wider reimbursement in Germany.